DUE

Impact of Inflammation on Brain Volume in Multiple Sclerosis [Original Contribution]

Objective  To study changes in brain volume measured monthly in patients treated for relapsing multiple sclerosis due to loss of tissue and the appearance of inflammation.

Drug-Induced Movement Disorders

Jack J. Chen, PharmD, FCCP, BCPS, CGP
Associate Professor
Loma Linda University
Loma Linda, CA

This comprehensive review covers approaches for both the recognition and management of drug-induced movement disorders. Pharmacotherapeutic approaches for treating akathisia, dystonia, Parkinsonism and tardive dyskinesia are explored. The importance of early detection via periodic assessment is discussed.

Are Extrapyramidal Symptoms Less Recognized? Case Report of Modern Practitioners’ Unfamiliarity with First Generation Antipsychotics

Tara L. Purvis, PharmD, BCPP
Veteran Affairs Sierra Nevada Healthcare System
Reno, Nevada 89502

The author received no support of any kind in writing this manuscript and has no potential conflicts of interest to disclose.  

The case report was published in Pharmacotherapy February 2011 and presented as a clinical pearl at the CPNP Annual Meeting. In that presentation however. emphasis was placed on the pharmacokinetics of fluphenazine decanoate.

A case is presented where initial suspicion of lithium toxicity was truly drug-induced Parkinsonism and tardive dyskinesia. The mistaken diagnosis underscores the need to improve training for movement disorder assessment.

Patient Question Regarding Invega Sustenna/ fluphenazine decanoate

Good morning- We have a 40 year old male patient with schizophrenia who recieved Invega Sustenna 234mg last Thursday, but does not want to continue with this medication due to increased agitation. He has been on Prolixin 20mg po qhs since 12/19 without ...

New Drug Review- Ezogabine (Potiga): Seizing the Seizure

Misty L. Gonzalez, PharmD, BCPP
Clinical Assistant Professor, Department of Pharmacy Practice
Southern Illinois University Edwardsville (SIUE)
School of Pharmacy

JR is a 33 year-old patient with complex partial seizures with secondary generalization who arrives to your medication management clinic. He has a significant history of anticonvulsant use and polytherapy, to which he has not responded optimally. JR is currently taking divalproex 1250 mg twice daily and topiramate 200 mg twice daily and continues to have monthly seizure episodes. He is highly motivated to become seizure-free. His neurologist is considering augmentation, but requests your expertise for an adjunctive agent.

New Drug Review: Gabapentin enacarbil extended release (Horizant™) – A New Formulation on the Horizon

Amy B. Werremeyer, PharmD, BCPP
Assistant Professor, Department of Pharmacy Practice
North Dakota State University
College of Pharmacy, Nursing and Allied Sciences

GR is a 57-year-old female who is not sleeping well due to her Restless Legs Syndrome.  She reports strong, irresistible urges to move her legs when she is watching TV at night, and these worsen when she lies in bed and tries to fall asleep. She currently takes ropinirole 4mg PO 2 hours before bedtime with some improvement in her symptoms, but she would like an even greater benefit from her medication. She has taken levodopa/carbidopa in the past for her restless legs, but she reported that the symptoms were occurring earlier in the day and were migrating into her arms while she was on it. GR would like to know if there are any additional treatments for her restless legs that may offer additional symptom relief.

Gabapentin enacarbil structure

[Articles] Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis

SummaryBackgroundThe global burden of disease attributable to seasonal influenza virus in children is unknown.

This page may contain content contributed by CPNP members or aggregated from other online sources. This content is provided as an unmoderated service to members for civil discussion and collaboration. Any opinions, conclusions, or recommendations are those of the author. If you come across any abuse or violation of the terms of use, please report the abuse.